CMND Reports CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Trial for Alcohol Use Disorder Vancouver, Canada, April 14, 2026
Clearmind Medicine Inc. Common Shares · Now $3.17
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS